02
Aug
2024
14:30
BST
09:30
EDT
15:30
CEST
Webinar
Cardiogenic Shock: Trial Updates and Future Directions
00
Days
00
Hours
00
Mins
00
Secs
![Cardiogenic Shock: Trial Updates and Future Directions](https://assets.radcliffecardiology.com/s3fs-public/webinar/2024-06/DELV-21897_IND_Shock_RF_1920x1080%20%281%29.jpg?VersionId=NX7fmBCJa7DRdezzuSeqLkk5Y2QjBICS)
Faculty:
![Babar Basir](https://assets.radcliffecardiology.com/s3fs-public/author/2022-09/Dr%20Babar%20Basir.png?VersionId=qk_troX3TW56wbkmkEA9HFi14ayNjZMM)
Babar Basir
![Balimkiz Senman](https://assets.radcliffecardiology.com/s3fs-public/author/2024-06/Dr%20Balimkiz%20Senman.png?VersionId=q00nTlUKA8PshJuXhjmtA4Xcona3bnN2)
Balimkiz Senman
Jacob E Møller
Overview
In this insightful webinar, Dr Babar Basir (Henry Ford Heart and Vascular Institute, Detroit, MI, US) is joined by Dr Balimkiz Senman (Duke University Hospital, Boston, MA, US) and Prof Jacob Møller (Odense University Hospital, Odense, DE) to delve into the findings of the DanGer Shock trial, recently presented at the American College of Cardiology (ACC) Conference in April 2024. This session will provide a comprehensive review of the trial, highlighting both its strengths and limitations.
The speakers will examine the design, methodology, and significant outcomes, offering an in-depth interpretation of the results and comparing them with findings from previous related studies. Additionally, the speakers will explore the clinical implications of these findings to discuss the next steps and potential future research sparked by the trial's conclusions.
Key References:
Møller, J, Engstrøm, T, Jensen, LO, et al. N Engl J Med. 2024 Apr 18;390(15):1382-1393. doi: 10.1056/NEJMoa2312572.
Thiele, H, Zeymer, U, Akin,I, et al. N Engl J Med. 2023 Oct 5;389(14):1286-1297. doi: 10.1056/NEJMoa2307227.
Thiele, H, Zeymer, U, Neumann, FJ, et al. N Engl J Med. 2012 Oct 4;367(14):1287-96. doi: 10.1056/NEJMoa1208410.
Agenda
Key Learning Objectives
- To review the results of the DanGer Shock trial
- To describe the limitations and strengths of the trial
- To describe the results of the trial in the context of previous conducted trials, including ECLS-Shock and IABP-Shock
- To discuss next steps forward in the management of AMI-CS
Target Audience
- Critical Care Clinicians
- Cardiologists
- Cardiac Surgeons
- Emergency Clinicians
Faculty Biographies
![Babar Basir](https://assets.radcliffecardiology.com/s3fs-public/author/2022-09/Dr%20Babar%20Basir.png?VersionId=qk_troX3TW56wbkmkEA9HFi14ayNjZMM)
Babar Basir
Dr Babar Basir is an Interventional Cardiologist at the Henry Ford Hospital in Detroit, Michigan, US.
Dr Basir specialises in the treatment of complex heart blockage with minimally invasive techniques using balloons and stents. He is a national leader in the treatment of cardiogenic shock and lectures around the world on the use of temporary heart pumps when the heart is failing.
![Balimkiz Senman](https://assets.radcliffecardiology.com/s3fs-public/author/2024-06/Dr%20Balimkiz%20Senman.png?VersionId=q00nTlUKA8PshJuXhjmtA4Xcona3bnN2)
Balimkiz Senman
Dr Balimkiz Senman is a cardiology fellow at Duke University Hospital in Boston, MA, US. Her research interests include cardiogenic shock, mechanical circulatory support, critical care and intervention.
Jacob E Møller
Prof Jacob Møller is clinical professor at the Odense University Hospital in Denmark. His main research interests include cardiogenic shock, mechanical circulatory support and invasive hemodynamic testing.